



**FIG. 1**



# FIG.2



## FIG.3

Formulation DEN1-2-3-4	No. Subjects	Mean Reactogenicity Index			No. viremic (cell culture)	Neutralizing Antibody to $\geq$ 3 serotypes
		1st dose	2nd dose	3rd dose		
LLLL	3	5	1	ND	1/3	2/3
HLLL	4	32	4	ND	3/4	4/4
LHLL	3	2	1	ND	3/3	0/3
LLLH	3	3	2	ND	1/3	0/3
LLHL	4	11	0	ND	4/4	1/4
LHLH	3	4	2	ND	1/3	0/3
HLHL	4	20	1	ND	4/4	2/4
LHHL	4	2	2	ND	0/4	1/4
LLHH	4	8	7	ND	2/4	1/4
HLLH	4	11	0	ND	2/4	4/4
HHLL	3	14	1	ND	3/3	3/3
LHHH	4	4	5	ND	0/4	1/4
HLHH	4	8	2	ND	1/4	3/4
HHLH	4	2	3	ND	1/4	4/4
HHHL	3	2	2	ND	0/3	2/3
HHHH	10	9	3	0	4/10	6/10
Total (mean)	64	(9)	(2)	(0)	47%	53%

\* 5 subjects received dose at 4 months, 4 of these 5 seroconverted to  $\geq$  3 serotypes.

H = undiluted reconstituted vaccine, L = 1.5 log dilution of H.

**FIG.4**


Volunteer	Vaccine	Schedule	Serotypes Neutralizing Ab Seroconversion 30 days after:		
			Dose 1	Dose 2	Dose 3
33	Full-dose Tetraval.	0,1	1,2,3,4	1,2,3,4	ND
34	Full-dose Tetraval.	0,1	2	1,2	ND
35	Full-dose Tetraval.	0,1	1,2,3,4	1,2,3,4	ND
36	Full-dose Tetraval.	0,1	1	1,3	ND
37	Full-dose Tetraval.	0,1,4	1	1	1,2,3
38	Full-dose Tetraval.	0,4	1,2	1,2,3	ND
39	Full-dose Tetraval.	0,1,4	1,3,4	1,3	1,2,3,4
40	Full-dose Tetraval.	0,1,4	1	1	1,3
41	Full-dose Tetraval.	0,1,4	2	2	1,2,3,4
42	Full-dose Tetraval.	0,1	2	1,2	ND

**FIG.5**


Formulation DEN1-2-3-4	Volunteer No.	Reactogenicity Index		Viremia <sup>1</sup>		Serotypes Neutralizing Antibody 30 days after: 1st dose      2nd dose	
		1st dose	2nd dose(1m)	1st dose	2nd dose	1st dose	2nd dose
HLLL	02-1	31	0	+	-	1,2,3,4	1,2,3,4
HLLL	02-2	23	0	-	-	1,2,3,4	1,3
HLLL	02-3	55	0	+	-	1,3,4	1,3
HLLL	02-4	18	0	+	+	1,2,3	1
HLLH	10-1	3	0	+	-	1,3	1,2,3,4
HLLH	10-2	0	0	-	-	1	1,2,3
HLLH	10-3	37	1	-	-	1,2,3	1,2,3
HLLH	10-4	5	0	+	-	1,2,3	1,3
HHLL	11-1	8	0	+	+	1,2,3	1
HHLL	11-2	20	2	+	-	1,2	1,2,3
HHLL	11-3	15	0	+	-	1,2,3	1,2
HLHH	13-1	6	4	-	-	1	1,4
HLHH	13-2	0	0	-	-	1,3,4	1,3,4
HLHH	13-3	4	0	-	-	1,2,*4	1,2,*4
HLHH	13-4	21	2	+	-	1,2,3,4	1,2,3,4
HHLH	14-1	0	0	-	-	1,2	1,2,3
HHLH	14-2	9	0	+	-	1,2,4	1,2,3,4
HHLH	14-3	0	2	-	-	None	1,2,3,4
HHLH	14-4	0	0	-	-	None	1,3,4
Mean		13.4	0.6				

1 hr delayed plaque method on C6/36 and Vero


## FIG.6A




## FIG.6B




### FIG.6C




### FIG.6D




### FIG.6E




### FIG.6F




# FIG.6G




# FIG.6H




# FIG.7A



# FIG.7B



# FIG.7C



# FIG.7D




FIG.8A

### Granzyme B gel band intensity\*

ID	Control	CD8dep	CD3dep	Unstim	Control	CD4dep
3	+++-	++++	+--	+--	++--	++--
4	++++	++++	++++			
10	++++	++++	+++-			
11	++++	++++	+--			
12*	++++	++++	+--			
13	++++	++++	+++-		++++	++++
15	++++	++++	+++-		++++	++++
16	++-	++-	+--	--	++++	++++
17	++++	++++	+--	--	++++	++++
20	++-	++-	++-			
22	++-	++-	+--	+--		
29	++++	++++	+--		++++	++++
31	++++	++++	+--	+--	++++	++++
33T	++-	+--	--			
35T*	++++	++++	+--	+--		
36T	++++	++++	+--	+--		

FIG.8B

